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B reast cancer is one of the most common cancers affecting women worldwide.  Thousands of young 
women are diagnosed with breast cancer every year 
[1 , 2].  Over the past four decades as diagnostic and 
treatment strategies (including surgery,  irradiation and 
systemic therapy) have improved,  the long-term out-
comes of breast cancer patients have also improved [3].  
Many patients with breast cancer can thus expect to live 
for many more years,  and this progress raises important 
of quality-of-life issues such as fertility,  which is partic-
ularly important for younger breast cancer patients 
[4 , 5].
Certain treatments for breast cancer,  including che-
motherapy and endocrine therapy,  may adversely affect 
fertility [1 , 6].  Breast cancer treatment can have signif-
icant side effects including a transient or permanent 
impairment of gonadal function and subsequent infer-
tility [7].  The duration of adjuvant endocrine therapy 
may also influence the timing of pregnancy for breast 
cancer patients.  Five years of adjuvant endocrine ther-
apy have traditionally been recommended,  and treat-
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Adverse effects on fertility are a significant problem for premenopausal breast cancer patients.  Since April 2009,  
we have been referring young patients for fertility counseling provided by a multidisciplinary team.  Here we 
evaluated the efficacy and safety of our current fertility preservation approach.  We retrospectively analyzed the 
cases of 277 patients < 45 years old at diagnosis,  which was made between 2009 and 2016.  Seventy-two (26%) 
patients received fertility counseling.  Seventeen (6%) of the 277 patients decided to preserve their fertility 
before starting adjuvant systemic therapy.  Six (35%) patients underwent oocyte cryopreservation,  and 11 (65%) 
married patients opted for embryo cryopreservation.  There were no pregnancies among the patients undergo-
ing oocyte cryopreservation,  whereas 3 (27%) of the patients who opted for embryo cryopreservation became 
pregnant.  Two (12%) patients stopped endocrine therapy after 2 years in an effort to become pregnant,  but 
their breast cancers recurred.  Though the problem of fertility loss for breast cancer patients is important and we 
should assess the infertility risk for all patients,  we should also consider the prognosis.  In June 2016,  we 
launched a prospective multicenter cohort study to evaluate the efficacy and safety of fertility preservation in 
greater detail.
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ment periods as long as 10 years have been recom-
mended for patients with hormone receptor-positive 
cancers [8].  The potential adverse impacts of treatment 
on fertility can be a significant problem for younger 
breast cancer patients [9].
Many women diagnosed with breast cancer are con-
cerned about the effects that cancer treatment may have 
on their fertility [9 , 10].  Ruddy et al.  reported that 
almost half of their series of 620 breast cancer patients 
were concerned about becoming infertile after treat-
ment,  and their retrospective study of fertility concerns 
revealed that fertility preservation strategies were 
desired by young women with breast cancer [11].  
However,  there have been very few prospective studies 
on the current state of breast cancer patients’ attitudes or 
on how fertility preservation impacts the outcomes of 
these patients,  and the efficacies of the available fertility 
preservation strategies remain poorly understood [12].
Since April of 2009,  we (at Okayama University 
Hospital) have referred such relatively young patients 
for fertility counseling with a multidisciplinary team 
including a gynecologist,  nurses and a counselor,  and 
we have both considered and resolved the problems 
pertaining to the management of fertility issues 
(Figs. 1 , 2).  We conducted the present study to evaluate 
the efficacy and safety of our current fertility preserva-
tion approach.
Methods
We performed a retrospective chart review of the 
cases of the 277 patients < 45 years old at the time of 
their breast cancer diagnosis at our institution during 
the period from April 2009 to December 2016.  The 
collected data included patient age at the time of diag-
nosis,  pathological diagnosis,  the number of children 
the patient had at the time of diagnosis,  tumor histol-
ogy,  nuclear grade,  hormone receptor and human epi-
dermal growth factor 2 (HER2) status,  Ki-67 positivity,  
cancer stage,  treatment regimens and duration,  fertility 
preservation methods,  number of successful pregnan-
cies,  and breast cancer recurrence.  All data were retro-
spectively extracted from our institution’s electronic 
medical records system.  This study was approved by the 
Ethical Committee of Okayama University Hospital 
(No. ken1708-024) and adhered to the Declaration of 
Helsinki.
Results
Patient characteristics. Sixty-eight (25%) patients 
were single,  183 (66%) were married,  and 26 (9%) were 
divorced.  Of the 183 married patients,  24 (13%) had 
one or more children and 159 (87%) had none.  All 26 
divorced patients had one or more children.  Seventy-
two (32%) patients received fertility counseling from the 
multidisciplinary team.  Of the 72 patients given fertility 
counseling,  34 (47%) were single,  35 (49%) were mar-
ried,  and 3 (13%) were divorced.  Of the 35 married 
patients who underwent fertility counseling,  13 (37%) 
already had one or more children and 22 (63%) were 
childless (Table 1).
Breast cancer patients with fertility preservation.
Of all 277 patients,  17 (6%) decided to preserve their 
fertility after counseling.  Six (35%) patients underwent 
oocyte cryopreservation,  and 11 (65%) of the married 
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Fig. 1　 Timeline of the multidisciplinary counseling system at 
Okayama University Hospital.
Fig. 2　 Flowchart of the counseling system at Okayama University 
Hospital.
patients opted for embryo cryopreservation.  The single 
patients preserved their oocytes,  and the married cou-
ples underwent embryos preservation.  At the time of 
diagnosis,  7 patients were single and underwent coun-
seling for fertility preservation.  One patient got married 
after receiving the diagnosis and then decided to 
undergo embryo preservation after her marriage.  
Ultimately,  6 patients underwent oocyte cryopreserva-
tion.
Thirteen (76%) patients received adjuvant chemo-
therapy.  The 13 (76%) patients with estrogen receptor 
(ER)-positive breast cancer were given adjuvant endo-
crine therapy,  and nine (53%) patients underwent both 
adjuvant chemotherapy and adjuvant endocrine therapy 
after fertility preservation.  There were no pregnancies 
among the patients who underwent oocyte cryopreser-
vation,  whereas 3 (27%) patients with ER-negative 
breast cancer who opted for embryo cryopreservation 
became pregnant at > 2 years after the primary opera-
tion.  Almost all of the ER-positive patients continued 
endocrine therapy,  but 2 (12%) patients stopped endo-
crine therapy after 2 years in order to try to become 
pregnant,  but their breast cancers recurred.  There were 
3 (18%) patients who opted to preserve fertility despite 
distant or local recurrence.  The other 2 patients with 
local recurrence who discontinued endocrine therapy 
had been undergoing endocrine therapy for 5 years 
(Table 2).
Discussion
In this case series study,  we evaluated the outcomes 
of our current multidisciplinary approach to fertility 
preservation for breast cancer patients.  Breast cancer 
treatment can have significant side effects including a 
transient or permanent impairment of gonadal function 
and subsequent infertility [7].  Most chemotherapeutic 
agents damage the growing cells in mature and imma-
ture follicles,  depending on the type of drug,  the dose,  
and the age of the patient,  and this may result in the 
depletion of many or all follicles.
For breast cancer treatment,  we have usually used 
alkylating agents,  including cyclophosphamide,  but 
these agents are quite toxic to the ovaries,  particularly 
to the primordial follicles,  which represent the ovarian 
reserve [13].  If the cancer is hormonal receptor-posi-
tive,  the duration of adjuvant endocrine therapy may 
also influence the timing of the patient’s pregnancy.  A 
high frequency of congenital abnormalities was 
reported to be related to the use of tamoxifen as the 
standard adjuvant endocrine therapy for premeno-
pausal patients,  before and during pregnancy [14].
Discussing the issue of fertility preservation is 
important for breast cancer patients who are of repro-
ductive age and may want to have children [15 , 16].  
Thus,  all young patients should consider and discuss 
this issue with healthcare providers at the time that they 
are scheduled to begin the treatment.  It is important for 
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Table 1　 Characteristics of patients ＜45 years old at diagnosis (from 2009 through 2016)
Marital
Status n (%)
Child
n (%)
Counseling
n (%)
Fertility
preservation
n (%)
Pregnancy/
Giving-birth
n (%)
Childrenʼs
age
Single 68(68/277,  25%)
34
(34/68,  50%)
7
(7/68,  10%)
0
0%
Married 183(183/277,  66%)
No 
children
24
(24/183,  13%)
13
(13/24,  54%)
7
(7/24,  29%)
2
(2/24,  8%)
#1:
2 years old
#2:
1 year old
≥1 child 159(159/183,  87%)
22
(22/159,  14%)
3
(3/159,  2%)
1
(1/159,  ＜1%) 1 year old
Divorced 26(26/277,  9%)
No 
children
3
(3/26,  12%)
0
0%
0
0%
0
0%
≥1
child
23
(23/26,  88%)
3
(3/23,  13%)
0
0%
0
0%
Total 277 72(72/277,  26%)
17
(17/277,  6%)
3
(3/277,  1%)
the healthcare provider team to recognize that patients 
may have concerns about fertility preservation.  Breast 
cancer patients often lack adequate knowledge of issues 
pertaining to their reproductive functions at the start of 
treatment,  and providing such information at the 
appropriate time allows the patient to select a treatment 
regimen without regrets [17].  Partridge et al.  reported 
that 73% of younger breast cancer survivors had at least 
minor concerns,  and 39% had major concerns about 
treatment-induced infertility [10 , 18].  They also dis-
cussed awareness issues in a study showing that only 
51% of breast cancer survivors were counseled about 
fertility preservation before starting treatment [10].  In 
our present series,  only 26% of the patients received 
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Table 2　 The 17 breast cancer patients with fertility preservation
Case Age Maritalstatus
Type of
preservation
Timing of
preservation Pathology Adjuvant treatment Pregnancy Recurrence
1 31 Single Egg POM1 T2N0 G3ER＋/HER2－ TC→TAM
2 32 Single Egg POM1 T2N3 G2ER＋/HER2－ AC→T→TAM
3 35 Single Egg POM2 T1N0 G2ER＋/HER2－ TC→TAM
4 37 Married,no children Embryo POM1
TisN0
ER＋ TAM (2yrs) Pregnant
5 38 Married,no children Embryo POM2
T2N0 G3
ER－/HER2＋ AC→T/H Pregnant
6 39 Married,no children Embryo POM1
T3N2 G1
ER＋/HER2－ AC→T→TAM (2 yrs) Distant
7 34 Married,no children Embryo POM1
T2N1 G3
ER＋/HER2－ AC→T→TAM (2 yrs) Local
8 36 Single Egg POM1 T2N1 G3ER－/HER2＋ AC→T/H
9 32 Married,no children Embryo POM1
T2N1 G3
ER＋/HER2－ AC→T→TAM Local
10 39 Single Embryo POM1 Bilateral isN0ER＋ TAM
11 33 Single Egg POM1 T1N0 G3ER－/HER2－ AC→T
12 36 Married,≥1 child Embryo POM1
T2N0 G3
ER－/HER2－ AC→T Pregnant
13 43 Married,no children Embryo Pre-operation
T1N0 G2
ER－/HER2－ TAM
14 35 Married,no children Embryo POM1
T2N1 G3
ER＋/HER2－ AC→T→TAM
15 39 Married,no children Embryo POM1
T1N0 G2
ER＋/HER2－ TAM
16 35 Married,no children Embryo POM1
T2N1 G3
ER＋/HER2－ TC→TAM
17 39 Married,≥1 child Embryo Pre-operation
T1N0 G2
ER＋/HER2－ TC→TAM
AC,  doxorubicin/cyclophosphamide; G,  histological grade; H,  trastuzumab; POM,  post-operative month; T,  paclitaxel; TAM,  tamoxi-
fen; TC,  docetaxel/cyclophosphamide.
counseling for fertility preservation before starting 
breast cancer treatment.  This rate was slightly lower 
than that reported by Ruddy et al.; their study also 
showed that concerns about fertility preservation are 
significantly affected by the social backgrounds of the 
patients and to vary among cultures worldwide [11].  As 
there have been no large prospective cohort studies 
focusing on this issue in Japan,  we do not know 
whether our results reflect the social background of 
women in Japan.  We thus need to plan a prospective 
cohort study with more patients.
In our study,  6 (35%) patients underwent oocyte 
cryopreservation and 11 (65%),  all of whom were mar-
ried,  opted for embryo cryopreservation.  The 3 preg-
nancies in our cohort were all due to embryo cryopres-
ervation.  Most of the patients who did use fertility 
preservation techniques reported that they underwent 
embryo cryopreservation,  the most efficacious of the 
widely available fertility preservation options.  Oocyte 
cryopreservation,  used by only 7 women in our cohort,  
is a newer technique that is generally offered to women 
who are unmarried [19].  The cryopreservation of ovar-
ian tissue was also attempted [20 , 21].
It can be very difficult for breast cancer patients to 
consider and make a decision regarding whether they 
should undergo fertility preservation,  given the prog-
nosis of their cancer.  It is therefore very useful for mul-
tidisciplinary team members to discuss this issue with 
the patient and her family.  Two of the present 17 
patients who underwent fertility preservation discon-
tinued endocrine therapy after 2 years in order to try to 
become pregnant.  Unfortunately,  however,  their breast 
cancers recurred.
A previous study suggested that pregnancy after 
breast cancer does not negatively impact the disease 
outcome and is safe for the offspring: a large,  multi-
center,  retrospective cohort study showed no difference 
in the disease-free survival rate between pregnant and 
non-pregnant patients with ER-positive breast cancer 
[22],  and there was no difference in outcomes between 
the patients who did and did not become pregnant.
The Breast International Group and the North 
American Breast Cancer Group launched a study to 
provide guidance for adopting customized strategies 
tailored to breast cancer patients wishing to become 
pregnant before completion of their entire course of 
adjuvant endocrine therapy [23].  This trial,  which is 
also evaluating the safety of pregnancy in breast cancer 
patients,  is anticipated to provide answers for future 
generations of young women who wish to interrupt 
their endocrine therapy in order to try to have a baby 
[23].
Our present case series study has limitations,  i.e.,  
the small patient number due to the single-institute 
nature of the study,  and the relatively short duration of 
follow-up.  More data obtained from a larger number of 
patients and with longer follow-ups are needed.
In conclusion,  we evaluated the current approach to 
fertility preservation at our institution.  Though the 
issue of fertility preservation for breast cancer patients is 
important and we should assess the infertility risk for all 
patients,  we should also consider the prognosis of their 
breast cancer.  However,  this was a single-institute and 
retrospective study,  and data from multicenter pro-
spective cohorts allowing evaluations of the efficacy and 
safety of fertility preservation are currently lacking in 
Japan.  Thus,  in June 2016 we launched a prospective 
multicenter cohort study to evaluate the efficacy and 
safety of fertility preservation in greater detail.  The 
population for the cohort is comprised of patients diag-
nosed with early breast cancer and registered as having 
undergone fertility preservation before the beginning of 
breast cancer treatment.  We will collect the data of the 
outcomes of the fertility preservation and the breast 
cancer prognoses.  The accrual goal is 50 patients for 5 
years.
Our present study focused on the importance of dis-
cussing fertility preservation with breast cancer patients.  
Patients with malignant diseases other than breast can-
cer such as leukemia,  lymphoma,  skin cancer,  ovarian 
cancer,  and sarcoma who may be treated by chemo-
therapy,  surgery or radiation therapy should also be 
considered.  A discussion with a multidisciplinary can-
cer care team of how the treatment may affect a patient’s 
future fertility should be conducted before the patient 
begins her treatment.
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